{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T14:48:57Z","timestamp":1790952537192,"version":"4.1.0"},"reference-count":58,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Psychiatric Research"],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1016\/j.jpsychires.2021.04.032","type":"journal-article","created":{"date-parts":[[2021,4,30]],"date-time":"2021-04-30T09:33:43Z","timestamp":1619775223000},"page":"444-452","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":28,"special_numbering":"C","title":["Efficacy and safety of antipsychotic treatments for schizophrenia: A systematic review and network meta-analysis of randomized trials in Japan"],"prefix":"10.1016","volume":"138","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9237-2236","authenticated-orcid":false,"given":"Taro","family":"Kishi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshikazu","family":"Ikuta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenji","family":"Sakuma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makoto","family":"Okuya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nakao","family":"Iwata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jpsychires.2021.04.032_bib1","unstructured":"031-95-003, Clinical evaluation pf aripiprazole in schizophrenic patients: a comparative double-blind study with mosapramine."},{"issue":"3","key":"10.1016\/j.jpsychires.2021.04.032_bib2","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1002\/pst.439","article-title":"Trial design issues and treatment effect modeling in multi-regional schizophrenia trials","volume":"9","author":"Chen","year":"2010","journal-title":"Pharmaceut. Stat."},{"issue":"4","key":"10.1016\/j.jpsychires.2021.04.032_bib3","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1097\/YIC.0000000000000123","article-title":"The effect of brexpiprazole (OPC-34712) and aripiprazole in adult patients with acute schizophrenia: results from a randomized, exploratory study","volume":"31","author":"Citrome","year":"2016","journal-title":"Int. Clin. Psychopharmacol."},{"issue":"3","key":"10.1016\/j.jpsychires.2021.04.032_bib4","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials","volume":"7","author":"DerSimonian","year":"1986","journal-title":"Contr. Clin. Trials"},{"issue":"1","key":"10.1016\/j.jpsychires.2021.04.032_bib5","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/gim.2016.80","article-title":"Prediction of CYP2D6 phenotype from genotype across world populations","volume":"19","author":"Gaedigk","year":"2017","journal-title":"Genet. Med."},{"issue":"11","key":"10.1016\/j.jpsychires.2021.04.032_bib6","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1007\/s100380200092","article-title":"Gene-based SNP discovery as part of the Japanese Millennium Genome Project: identification of 190,562 genetic variations in the human genome. Single-nucleotide polymorphism","volume":"47","author":"Haga","year":"2002","journal-title":"J. Hum. Genet."},{"issue":"1","key":"10.1016\/j.jpsychires.2021.04.032_bib7","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.schres.2009.05.030","article-title":"Effectiveness of second-generation antipsychotics with acute-phase schizophrenia","volume":"113","author":"Hatta","year":"2009","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.jpsychires.2021.04.032_bib8","author":"Higgins"},{"issue":"2","key":"10.1016\/j.jpsychires.2021.04.032_bib9","doi-asserted-by":"crossref","DOI":"10.1111\/appy.12352","article-title":"Lurasidone in the treatment of schizophrenia: results of a double-blind, placebo-controlled trial in Asian patients","volume":"11","author":"Higuchi","year":"2019","journal-title":"Asia Pac. Psychiatr."},{"issue":"3","key":"10.1016\/j.jpsychires.2021.04.032_bib10","doi-asserted-by":"crossref","DOI":"10.1111\/appy.12354","article-title":"Randomized, double-blind, placebo, and risperidone-controlled study of lurasidone in the treatment of schizophrenia: results of an inconclusive 6-week trial","volume":"11","author":"Higuchi","year":"2019","journal-title":"Asia Pac. Psychiatr."},{"key":"10.1016\/j.jpsychires.2021.04.032_bib11","first-page":"2077","article-title":"A double-blind, placebo-controlled, comparative study of paliperidone Extended-Release (ER) tablets in patients with schizophrenia","volume":"13","author":"Hirayasu","year":"2010","journal-title":"Jpn. J. Clin. Psychopharmacol."},{"key":"10.1016\/j.jpsychires.2021.04.032_bib12","series-title":"European College of Neuropsychopharmacology Workshop for Junior Scientists in Europe, Nice, France","article-title":"Blonanserin versus aripiprazole for treatment of Japanese schizophrenia patients: a randomized control trial","author":"Hori","year":"2015"},{"key":"10.1016\/j.jpsychires.2021.04.032_bib13","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/S0140-6736(19)31135-3","article-title":"Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis","volume":"394","author":"Huhn","year":"2019","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.jpsychires.2021.04.032_bib14","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1046\/j.1440-1819.2001.00882.x","article-title":"Olanzapine versus haloperidol in the treatment of patients with chronic schizophrenia: results of the Japan multicenter, double-blind olanzapine trial","volume":"55","author":"Ishigooka","year":"2001","journal-title":"Psychiatr. Clin. Neurosci."},{"issue":"9","key":"10.1016\/j.jpsychires.2021.04.032_bib15","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1111\/pcn.12682","article-title":"Efficacy and safety of brexpiprazole for the treatment of acute schizophrenia in Japan: a 6-week, randomized, double-blind, placebo-controlled study","volume":"72","author":"Ishigooka","year":"2018","journal-title":"Psychiatr. Clin. Neurosci."},{"issue":"2","key":"10.1016\/j.jpsychires.2021.04.032_bib16","first-page":"295","article-title":"Clinical evaluation of aripiprazole in schizophrenic patients: a comparative double-blind study with haloperidol","volume":"9","author":"Ishigooka","year":"2006","journal-title":"Japanese journal of clinical psychopharmacology"},{"issue":"2","key":"10.1016\/j.jpsychires.2021.04.032_bib17","first-page":"160","article-title":"Open-label, randomized trial of treatment of acute schizophrenia with olanzapine compared paliperidone ER","volume":"19","author":"Ishizuka","year":"2011","journal-title":"Psychiatry (Japanese)"},{"key":"10.1016\/j.jpsychires.2021.04.032_bib18","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/j.schres.2019.07.055","article-title":"Efficacy and safety of blonanserin transdermal patch in patients with schizophrenia: a 6-week randomized, double-blind, placebo-controlled, multicenter study","volume":"215","author":"Iwata","year":"2020","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.jpsychires.2021.04.032_bib19","doi-asserted-by":"crossref","first-page":"15067","DOI":"10.1038\/nrdp.2015.67","article-title":"Schizophrenia","volume":"1","author":"Kahn","year":"2015","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.jpsychires.2021.04.032_bib20","first-page":"177","article-title":"A double-blind comparison of new iminodibenzyl compound Y-516 with clocapramine in the phamacotherapy of schizophrenia","volume":"17","author":"Kato","year":"1989","journal-title":"Clinical Evaluation"},{"issue":"2","key":"10.1016\/j.jpsychires.2021.04.032_bib21","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1093\/schbul\/13.2.261","article-title":"The positive and negative syndrome scale (PANSS) for schizophrenia","volume":"13","author":"Kay","year":"1987","journal-title":"Schizophr. Bull."},{"issue":"6","key":"10.1016\/j.jpsychires.2021.04.032_bib22","doi-asserted-by":"crossref","first-page":"856","DOI":"10.4088\/JCP.11r07539","article-title":"Exploratory analyses of efficacy data from schizophrenia trials in support of new drug applications submitted to the US Food and Drug Administration","volume":"73","author":"Khin","year":"2012","journal-title":"J. Clin. Psychiatr."},{"issue":"14","key":"10.1016\/j.jpsychires.2021.04.032_bib23","doi-asserted-by":"crossref","first-page":"2663","DOI":"10.1007\/s00213-016-4295-9","article-title":"Efficacy and safety of asenapine in Asian patients with an acute exacerbation of schizophrenia: a multicentre, randomized, double-blind, 6-week, placebo-controlled study","volume":"233","author":"Kinoshita","year":"2016","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.jpsychires.2021.04.032_bib24","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.2147\/NDT.S134340","article-title":"Comparative efficacy and safety of antipsychotics in the treatment of schizophrenia: a network meta-analysis in a Japanese population","volume":"13","author":"Kishi","year":"2017","journal-title":"Neuropsychiatric Dis. Treat."},{"key":"10.1016\/j.jpsychires.2021.04.032_bib25","doi-asserted-by":"crossref","first-page":"3041","DOI":"10.2147\/NDT.S121588","article-title":"A randomized trial of aripiprazole vs blonanserin for the treatment of acute schizophrenia and related disorders","volume":"12","author":"Kishi","year":"2016","journal-title":"Neuropsychiatric Dis. Treat."},{"issue":"16","key":"10.1016\/j.jpsychires.2021.04.032_bib26","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1056\/NEJMoa1911772","article-title":"A non-D2-receptor-binding drug for the treatment of schizophrenia","volume":"382","author":"Koblan","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jpsychires.2021.04.032_bib27","first-page":"233","article-title":"Clinical evaluation of risperidone in schizophrenia: a double-blind comparative study of risperidone with clocapramine","volume":"23","author":"Kudo","year":"1994","journal-title":"Japanese Journal of Clinical Psychiatry"},{"key":"10.1016\/j.jpsychires.2021.04.032_bib28","first-page":"207","article-title":"Clinical ecaluation of a serotonin-2 and dopamine-2 receptor antagonist (SDA), perospirone HCI on schizophrenia -A comparative double-blind study with mosapramine HCI-","volume":"24","author":"Kudo","year":"1997","journal-title":"Clin. Eval."},{"key":"10.1016\/j.jpsychires.2021.04.032_bib29","first-page":"529","article-title":"A double-blind comparison of Y-516 with haloperidol in schizophrenic patients","volume":"152","author":"Kudo","year":"1990","journal-title":"Journal of Clinical and Experimental Medicine"},{"issue":"12","key":"10.1016\/j.jpsychires.2021.04.032_bib30","first-page":"1807","article-title":"Clinical evaluation of quetiapine fumarate for the treatment of schizophrenia: a double blind controlled study using mosapramine hydrochloride as a control","volume":"16","author":"Kudo","year":"2000","journal-title":"Journal of Clinical Therapeutics & Medicines"},{"issue":"4","key":"10.1016\/j.jpsychires.2021.04.032_bib31","first-page":"519","article-title":"Clinical evaluation of clocapramine (Clofekton) in schizophrenia: a double blind comparison of clocapramine, haloperidol and perphenazine","volume":"12","author":"Kurihara","year":"1983","journal-title":"Japanese Journal of Clinical Psychiatry"},{"key":"10.1016\/j.jpsychires.2021.04.032_bib32","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.schres.2018.05.009","article-title":"60 years of placebo-controlled antipsychotic drug trials in acute schizophrenia: meta-regression of predictors of placebo response","volume":"201","author":"Leucht","year":"2018","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.jpsychires.2021.04.032_bib33","doi-asserted-by":"crossref","DOI":"10.1016\/j.euroneuro.2014.02.006","article-title":"Geographic variation in efficacy of atypical antipsychotics for the acute treatment of schizophrenia - an individual patient data meta-analysis","author":"Mattila","year":"2014","journal-title":"Eur. Neuropsychopharmacol : the journal of the European College of Neuropsychopharmacology"},{"key":"10.1016\/j.jpsychires.2021.04.032_bib34","first-page":"297","article-title":"Clinical evaluation of blonanserin for schizophrenia -A randomized study comparing blonanserin with riperidone-","volume":"11","author":"Miura","year":"2008","journal-title":"Jpt. J. Clin. Psychopharmacol."},{"key":"10.1016\/j.jpsychires.2021.04.032_bib35","doi-asserted-by":"crossref","first-page":"b2535","DOI":"10.1136\/bmj.b2535","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"339","author":"Moher","year":"2009","journal-title":"Bmj"},{"issue":"2","key":"10.1016\/j.jpsychires.2021.04.032_bib36","first-page":"177","article-title":"Regional cerebral blood flow in schizophrenia: effects of haloperidol and risperidone treatment","volume":"10","author":"Mori","year":"1999","journal-title":"Brain Science and Mental Disorders (Japanese)"},{"key":"10.1016\/j.jpsychires.2021.04.032_bib37","first-page":"2059Y2079","article-title":"Clinical evaluation of blonanserin for schizophrenia: a double-blind trial comparing blonanserin with haloperidol","volume":"10","author":"Murasaki","year":"2007","journal-title":"Jpn J Clin Psychopharmacol"},{"issue":"1","key":"10.1016\/j.jpsychires.2021.04.032_bib38","first-page":"127","article-title":"Clinical evaluation of quetiapine fumarate on schizophrenia: comparative double-blind study with haloperidol","volume":"4","author":"Murasaki","year":"2001","journal-title":"Japanese Journal of Clinical Psychiatry"},{"key":"10.1016\/j.jpsychires.2021.04.032_bib39","first-page":"159","article-title":"Clinical ecaluation of a new antipsychotic, perospirone HCI, on schizophrenia -A comparative double-blind study with haloperidol-","volume":"24","author":"Murasaki","year":"1997","journal-title":"Clin. Eval."},{"key":"10.1016\/j.jpsychires.2021.04.032_bib40","first-page":"221","article-title":"Efficacy of new antipsychotic, risperidone, on schizophrenia -A comparative double-blind study with haloperidol-","volume":"21","author":"Murasaki","year":"1993","journal-title":"Clin. Eval."},{"issue":"3","key":"10.1016\/j.jpsychires.2021.04.032_bib41","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1111\/j.1440-1819.2009.01947.x","article-title":"Randomized clinical comparison of perospirone and risperidone in patients with schizophrenia: kansai Psychiatric Multicenter Study","volume":"63","author":"Okugawa","year":"2009","journal-title":"Psychiatr. Clin. Neurosci."},{"key":"10.1016\/j.jpsychires.2021.04.032_bib42","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/S0140-6736(15)01121-6","article-title":"Schizophrenia","volume":"388","author":"Owen","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.jpsychires.2021.04.032_bib43","article-title":"A 6-week, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of lurasidone (SM-13496) in acutely psychotic subjects with schizophrenia","author":"P3-J066","year":"2020","journal-title":"EudraCT.PMDA"},{"key":"10.1016\/j.jpsychires.2021.04.032_bib44","author":"R\u00fccker"},{"issue":"12","key":"10.1016\/j.jpsychires.2021.04.032_bib45","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1001\/jamapsychiatry.2014.1319","article-title":"Placebo response in antipsychotic clinical trials: a meta-analysis","volume":"71","author":"Rutherford","year":"2014","journal-title":"JAMA Psychiatry"},{"issue":"7","key":"10.1016\/j.jpsychires.2021.04.032_bib46","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0099682","article-title":"Evaluating the quality of evidence from a network meta-analysis","volume":"9","author":"Salanti","year":"2014","journal-title":"PloS One"},{"key":"10.1016\/j.jpsychires.2021.04.032_bib47","series-title":"European College of Neuropsychopharmacology 26th Annual Meeting. Barcelona, Spain","article-title":"Safety of blonanserin (BNS) and paliperidone extended-release (PAL-ER) in patients with acute schizophrenia","author":"Sanada","year":"2013"},{"issue":"4","key":"10.1016\/j.jpsychires.2021.04.032_bib48","first-page":"75","article-title":"The neurocognitive effects of aripiprazole compared with risperidone in the treatment of schizophrenia","volume":"61","author":"Sato","year":"2012","journal-title":"Hiroshima J. Med. Sci."},{"issue":"9351","key":"10.1016\/j.jpsychires.2021.04.032_bib49","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/S0140-6736(03)12151-4","article-title":"Obesity and type 2 diabetes in Japanese patients","volume":"361","author":"Sone","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.jpsychires.2021.04.032_bib50","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1186\/1471-244X-10-89","article-title":"Impact of race on efficacy and safety during treatment with olanzapine in schizophrenia, schizophreniform or schizoaffective disorder","volume":"10","author":"Stauffer","year":"2010","journal-title":"BMC Psychiatr."},{"issue":"2","key":"10.1016\/j.jpsychires.2021.04.032_bib51","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1007\/s00213-007-0872-2","article-title":"How effective is it to sequentially switch among Olanzapine, Quetiapine and Risperidone?--A randomized, open-label study of algorithm-based antipsychotic treatment to patients with symptomatic schizophrenia in the real-world clinical setting","volume":"195","author":"Suzuki","year":"2007","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.jpsychires.2021.04.032_bib52","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.pnpbp.2012.09.010","article-title":"A 12-week randomized, open-label study of perospirone versus aripiprazole in the treatment of Japanese schizophrenia patients","volume":"40","author":"Takekita","year":"2013","journal-title":"Progress in neuro-psychopharmacology & biological psychiatry"},{"issue":"4","key":"10.1016\/j.jpsychires.2021.04.032_bib53","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1002\/jrsm.1054","article-title":"Automating network meta-analysis","volume":"3","author":"van Valkenhoef","year":"2012","journal-title":"Res. Synth. Methods"},{"issue":"2","key":"10.1016\/j.jpsychires.2021.04.032_bib54","first-page":"169","article-title":"Comparison of clinical efficacy of clozapine and haloperidol in scizophrenia using double-blind technique","volume":"2","author":"Yagi","year":"1974","journal-title":"Clin. Eval."},{"issue":"11","key":"10.1016\/j.jpsychires.2021.04.032_bib55","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.4088\/JCP.v65n1114","article-title":"Effects of changing from typical to atypical antipsychotic drugs on subjective sleep quality in patients with schizophrenia in a Japanese population","volume":"65","author":"Yamashita","year":"2004","journal-title":"J. Clin. Psychiatr."},{"key":"10.1016\/j.jpsychires.2021.04.032_bib56","series-title":"The Japanese Society of Clinical Neuropsychopharmacology 25th Annual Meeting","article-title":"Comparison of drug attitude and adherence between blonanserin and risperidone in patients with schizophrenia","author":"Yanagimoto","year":"2015"},{"issue":"9548","key":"10.1016\/j.jpsychires.2021.04.032_bib57","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1016\/S0140-6736(06)69703-1","article-title":"Epidemic obesity and type 2 diabetes in Asia","volume":"368","author":"Yoon","year":"2006","journal-title":"Lancet"},{"issue":"Suppl. 1","key":"10.1016\/j.jpsychires.2021.04.032_bib58","first-page":"1","article-title":"Pharmacogenetics of antipsychotic drug treatment: update and clinical implications","volume":"5","author":"Yoshida","year":"2020","journal-title":"Mol Neuropsychiatry"}],"container-title":["Journal of Psychiatric Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022395621002594?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022395621002594?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,12,17]],"date-time":"2024-12-17T00:13:06Z","timestamp":1734394386000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022395621002594"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6]]},"references-count":58,"alternative-id":["S0022395621002594"],"URL":"https:\/\/doi.org\/10.1016\/j.jpsychires.2021.04.032","relation":{},"ISSN":["0022-3956"],"issn-type":[{"value":"0022-3956","type":"print"}],"subject":[],"published":{"date-parts":[[2021,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and safety of antipsychotic treatments for schizophrenia: A systematic review and network meta-analysis of randomized trials in Japan","name":"articletitle","label":"Article Title"},{"value":"Journal of Psychiatric Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpsychires.2021.04.032","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}